BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32521103)

  • 21. Design, Synthesis, and Biological Activity of Isosyringolin A.
    Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
    Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
    Ge Y; Li A; Wu J; Feng H; Wang L; Liu H; Xu Y; Xu Q; Zhao L; Li Y
    Eur J Med Chem; 2017 Mar; 128():180-191. PubMed ID: 28182990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
    Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
    Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
    Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
    Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
    Jorda R; Dušek J; Řezníčková E; Pauk K; Magar PP; Imramovský A; Kryštof V
    Eur J Med Chem; 2017 Jul; 135():142-158. PubMed ID: 28441582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
    Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
    Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
    Yu J; Xu L; Hong D; Zhang X; Liu J; Li D; Li J; Zhou Y; Liu T
    Eur J Med Chem; 2019 Jan; 161():543-558. PubMed ID: 30391816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Electrochemical assay for 20S proteasome activity and inhibition with anti-cancer drugs.
    Henriques de Jesus CS; Chiorcea-Paquim AM; Barsan MM; Diculescu VC
    Talanta; 2019 Jul; 199():32-39. PubMed ID: 30952265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reporter PET Images Bortezomib Treatment-Mediated Suppression of Cancer Cell Proteasome Activity.
    Lee JH; Jung KH; Quach CHT; Park JW; Moon SH; Cho YS; Lee KH
    Sci Rep; 2018 Aug; 8(1):12290. PubMed ID: 30116045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
    Schrader J; Henneberg F; Mata RA; Tittmann K; Schneider TR; Stark H; Bourenkov G; Chari A
    Science; 2016 Aug; 353(6299):594-8. PubMed ID: 27493187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
    Ri M
    Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
    Xi J; Zhuang R; Kong L; He R; Zhu H; Zhang J
    Eur J Med Chem; 2019 Nov; 182():111646. PubMed ID: 31521028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
    Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S
    J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
    Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
    Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. α-Tocotrienol and Redox-Silent Analogs of Vitamin E Enhances Bortezomib Sensitivity in Solid Cancer Cells through Modulation of NFE2L1.
    Ishii K; Hido M; Sakamura M; Virgona N; Yano T
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.
    Zhuang R; Gao L; Lv X; Xi J; Sheng L; Zhao Y; He R; Hu X; Shao Y; Pan X; Liu S; Huang W; Zhou Y; Li J; Zhang J
    Eur J Med Chem; 2017 Jan; 126():1056-1070. PubMed ID: 28027531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening.
    Miller Z; Kim KS; Lee DM; Kasam V; Baek SE; Lee KH; Zhang YY; Ao L; Carmony K; Lee NR; Zhou S; Zhao Q; Jang Y; Jeong HY; Zhan CG; Lee W; Kim DE; Kim KB
    J Med Chem; 2015 Feb; 58(4):2036-41. PubMed ID: 25658656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.
    Skorda A; Sklirou AD; Sakellaropoulos T; Gianniou DD; Kastritis E; Terpos E; Tsitsilonis OE; Florea BI; Overkleeft HS; Dimopoulos MA; Alexopoulos LG; Trougakos IP
    J Cell Mol Med; 2019 Dec; 23(12):8010-8018. PubMed ID: 31568628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor.
    Robinson RM; Reyes L; Duncan RM; Bian H; Strobel ED; Hyman SL; Reitz AB; Dolloff NG
    Eur J Med Chem; 2020 Jan; 186():111906. PubMed ID: 31787362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Profound activity of the anti-cancer drug bortezomib against Echinococcus multilocularis metacestodes identifies the proteasome as a novel drug target for cestodes.
    Stadelmann B; Aeschbacher D; Huber C; Spiliotis M; Müller J; Hemphill A
    PLoS Negl Trop Dis; 2014 Dec; 8(12):e3352. PubMed ID: 25474446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.